Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 954,229 shares of RXRX, which is worth approximately $4.49 Million. The most recent transaction as insider was on Apr 06, 2022, when has been sold 18,500 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 954K

4.06% 3M change

25.12% 12M change

Total Value Held $4.49 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 06 2022	BUY Conversion of derivative security	-	18,500 Added 5.68%	307,242 Class A Common Stock
Apr 05 2022	SELL Open market or private sale	$256,816 $7.45 p/Share	34,472 Reduced 11.63%	262,058 Class A Common Stock
Apr 05 2022	BUY Exercise of conversion of derivative security	$109,145 $2.48 p/Share	44,010 Added 13.67%	278,030 Class A Common Stock
Apr 05 2022	BUY Conversion of derivative security	-	18,500 Added 6.19%	280,558 Class A Common Stock
Mar 15 2022	SELL Open market or private sale	$37,392 $6.08 p/Share	6,150 Reduced 2.56%	234,020 Class A Common Stock
Mar 15 2022	BUY Conversion of derivative security	-	6,150 Added 2.5%	240,170 Class A Common Stock
Mar 14 2022	SELL Open market or private sale	$1,444,400 $6.28 p/Share	230,000 Reduced 49.57%	234,020 Class A Common Stock
Mar 14 2022	BUY Conversion of derivative security	-	230,000 Added 33.14%	464,020 Class A Common Stock
Mar 11 2022	SELL Open market or private sale	$695,000 $6.95 p/Share	100,000 Reduced 29.94%	234,020 Class A Common Stock
Mar 11 2022	BUY Conversion of derivative security	-	100,000 Added 23.04%	334,020 Class A Common Stock
Mar 07 2022	SELL Open market or private sale	$2,190,000 $7.3 p/Share	300,000 Reduced 56.18%	234,020 Class A Common Stock
Mar 07 2022	BUY Conversion of derivative security	-	300,000 Added 35.97%	534,020 Class A Common Stock
Feb 22 2022	SELL Open market or private sale	$1,022,000 $10.22 p/Share	100,000 Reduced 29.94%	234,020 Class A Common Stock
Feb 22 2022	BUY Conversion of derivative security	-	100,000 Added 23.04%	334,020 Class A Common Stock
Feb 04 2022	SELL Payment of exercise price or tax liability	$3,910 $11.4 p/Share	343 Reduced 0.15%	234,020 Class A Common Stock
Feb 04 2022	BUY Grant, award, or other acquisition	-	210,893 Added 47.36%	234,363 Class A Common Stock
Jan 31 2022	SELL Open market or private sale	$232,934 $11.73 p/Share	19,858 Reduced 45.83%	23,470 Class A Common Stock
Jan 31 2022	BUY Conversion of derivative security	-	19,858 Added 31.43%	43,328 Class A Common Stock
Jan 14 2022	SELL Open market or private sale	$3,446,780 $13.57 p/Share	254,000 Reduced 91.54%	23,470 Class A Common Stock
Jan 14 2022	BUY Conversion of derivative security	-	254,000 Added 47.79%	277,470 Class A Common Stock
Jan 13 2022	SELL Open market or private sale	$1,271,070 $14.61 p/Share	87,000 Reduced 78.75%	23,470 Class A Common Stock
Jan 13 2022	BUY Conversion of derivative security	-	87,000 Added 44.06%	110,470 Class A Common Stock
Dec 16 2021	SELL Open market or private sale	$4,000 $20.0 p/Share	200 Reduced 0.84%	23,470 Class A Common Stock
Dec 16 2021	BUY Conversion of derivative security	-	200 Added 0.84%	23,670 Class A Common Stock
Dec 13 2021	SELL Open market or private sale	$2,002 $20.02 p/Share	100 Reduced 0.42%	23,470 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account